---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-012864"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T06:57:02.999396+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro receives Nasdaq MVLS deficiency notice; stockholders approve reverse stock split

## Summary
- Nasdaq notice on Sep 26, 2023: MVLS below $35M for 30 consecutive business days.
- Cure period: 180 days until Mar 25, 2024; need $35M+ MVLS for 10 consecutive days.
- Stockholders on Sep 29, 2023 approved reverse split (ratio 1:2 to 1:20) at board discretion.
- Vote tally: 58,463,491 for, 9,749,936 against, 44,645 abstain, 1,609,492 broker non-votes.
- If compliance not regained by Mar 25, 2024, Nasdaq will delist; no immediate listing impact.

## SEC filing metadata
- accession: 0001214659-23-012864
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012864/0001214659-23-012864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012864/b9262308k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-012864
- JSON: https://secwatch.observer/filing/0001214659-23-012864.json
- Plain text: https://secwatch.observer/filing/0001214659-23-012864.txt

## Key facts
- Listing & Compliance Notices
  Alzamend Neuro, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: September 26, 2023, Alzamend Neuro, Inc. (the “Company” ) received a notice from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“ MVLS ”) for the Company’s common stock, par value $0.0001 per share (the “Common Stock” ), was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Rule ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or unt
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012864/0001214659-23-012864-index.htm
- Shareholder Votes
  Alzamend Neuro, Inc. shareholders approved Approval of the amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2024 at the 2023-09-29 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-09-29
  source text: Proposal One : Approval of the amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2024, with the exact ratio to be set at a whole number within this range as determined by the Company’s Board of Directors in its sole discretion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012864/0001214659-23-012864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.